Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 9/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.50 |
| ▸ | TNF | P01375 | 4/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19396095 | 0.89 | TRPA1 (0.59) | TRPA1ADORA2BTNFUSP2LMNA | |
| SCHEMBL17609739 | 0.87 | TRPA1 (0.76) | TRPA1ADORA2B | |
| SCHEMBL17609740 | 0.87 | TRPA1 (0.76) | TRPA1ADORA2B | |
| SCHEMBL17609832 | 0.85 | TRPA1 (0.55) | TRPA1 | |
| SCHEMBL17609572 | 0.85 | TRPA1 (0.77) | TRPA1ADORA2B | |
| SCHEMBL17609737 | 0.85 | TRPA1 (0.77) | TRPA1 | |
| SCHEMBL17609574 | 0.85 | TRPA1 (0.77) | TRPA1ADORA2B | |
| SCHEMBL17609735 | 0.85 | TRPA1 (0.77) | TRPA1 | |
| SCHEMBL17609868 | 0.85 | TRPA1 (0.61) | TRPA1ADORA2B | |
| SCHEMBL17609869 | 0.85 | TRPA1 (0.61) | TRPA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452279-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | Metro International Biotech, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-11878994-B1 | Compositions for treatment of inflammation | METRO INTERNATIONAL BIOTECH, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| WO-2023122190-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | METRO INTERNATIONAL BIOTECH, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122190-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION | METRO INTERNATIONAL BIOTECH, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878994-B1 | Compositions for treatment of inflammation | NQO1, NAMPT, MPO | TRPA1 4054/4885ADORA2B 1104/4885TNF 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.